1995
DOI: 10.1097/00002060-199503000-00048
|View full text |Cite
|
Sign up to set email alerts
|

Effect of Mexiletine on Spinal Cord Dysesthetic Pain

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
34
0
3

Year Published

1998
1998
2016
2016

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 32 publications
(38 citation statements)
references
References 0 publications
1
34
0
3
Order By: Relevance
“…This could be due to the use of a relatively smaller dose (450 mg/day) than the 750 mg/day shown to be beneficial in patients with chronic non-SCI neuropathic pain. 54 There was strong evidence that intravenous ketamine is effective in the treatment of post-SCI central or neuropathic pain. 55,56 Ketamine has been shown to be especially effective in treating wind-up pain, which may be due to the fact that temporal summation of pain (windup pain) is mediated by NMDA receptors.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…This could be due to the use of a relatively smaller dose (450 mg/day) than the 750 mg/day shown to be beneficial in patients with chronic non-SCI neuropathic pain. 54 There was strong evidence that intravenous ketamine is effective in the treatment of post-SCI central or neuropathic pain. 55,56 Ketamine has been shown to be especially effective in treating wind-up pain, which may be due to the fact that temporal summation of pain (windup pain) is mediated by NMDA receptors.…”
Section: Discussionmentioning
confidence: 99%
“…Chiou-Tan et al 54 provided 15 SCI individuals with either oral mexiletine (an orally administered derivative of lidocaine) or placebo (150mg 3 × daily) in a double-blind crossover RCT. There was no appreciable improvement in pain severity, as measured either on a VAS or using the McGill Pain Questionnaire, within either group.…”
Section: Analgesics For Sci Painmentioning
confidence: 99%
“…A prospective, placebo-controlled RCT in a population of patients with SCI-related NP found that mexiletine was not significantly more effective than placebo in reducing pain intensity. 48 THERAPIES REQUIRING FURTHER RESEARCH It should be strongly emphasized that the overall body of evidence for the management of at-and below-level NP is inadequate. This includes the evidence that has been used to support recommendations put forward by our group.…”
Section: Recommendation 211mentioning
confidence: 99%
“…31 A controlled study using mexiletine found no significant advantage over placebo. 32 A relatively large randomised controlled trial has been performed with the anticonvulsant pregabalin but the results are as yet unpublished. Other anticonvulsants such as sodium valproate, 33 carbamazepine, 24 lamotrigine, 34 and topiramate 35 are effective in some individuals.…”
Section: At-level and Below-level Neuropathic Painmentioning
confidence: 99%